Key Updates in the 2026 American Diabetes Association Standards of Care

This activity highlights key updates in the 2026 ADA Standards of Care, focusing on changes that impact pharmacist-led medication selection, monitoring, and patient counseling. Updates to glucose-lowering therapies, diabetes technology, and cardiovascular, kidney, and obesity management will be reviewed to support evidence-based diabetes care. 

Learning Objectives:

At the completion of this activity, the pharmacist will be able to:

1. Identify key changes in the 2026 American Diabetes Association Standards of Care that impact medication selection, monitoring, and patient counseling. 
2. Describe updates to glucose-lowering therapies and diabetes technology, including expanded use of continuous glucose monitoring (CGM), automated insulin delivery, and newer pharmacologic agents. 
3. Apply updated recommendations for cardiovascular, kidney, and obesity management to optimize medication therapy management and collaborative care. 

At the completion of this activity, the technician will be able to:
1. Identify key changes in the 2026 American Diabetes Association Standards of Care that impact medication selection, monitoring, and patient counseling. 
2. Describe updates to glucose-lowering therapies and diabetes technology, including expanded use of continuous glucose monitoring (CGM), automated insulin delivery, and newer pharmacologic agents. 

Texas Pharmacy Association (154) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Continuing education will be provided to participants who completed all course requirements.
ACPE 0154-0000-26-002-H01-P
ACPE 0154-0000-26-002-H01-P
1 Contact Hour (0.1 CEU)
Knowledge-based